Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Sponsor: University of Arizona
A PHASE2 clinical study on Metastatic Pancreatic Cancer and Pancreatic Cancer, this trial is ongoing. The trial is conducted by University of Arizona and has accumulated 18 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
18 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Aug 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE2
▶ Show 13 earlier versions
-
Nov 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Jan 2022 — Jan 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Arizona
For direct contact, visit the study record on ClinicalTrials.gov .